Neurocrine Biosciences (NBIX) Stock Forecast, Price & News

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

Is Neurocrine Biosciences a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Neurocrine Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NBIX, but not buy additional shares or sell existing shares.
View analyst ratings for Neurocrine Biosciences or view top-rated stocks.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Neurocrine Biosciences.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Wednesday, May, 4th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by $0.21. The business had revenue of $310.60 million for the quarter, compared to analysts' expectations of $304.07 million. Neurocrine Biosciences had a net margin of 5.91% and a trailing twelve-month return on equity of 5.30%. Neurocrine Biosciences's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.33 EPS.
View Neurocrine Biosciences' earnings history.

What price target have analysts set for NBIX?

17 brokerages have issued 1 year target prices for Neurocrine Biosciences' shares. Their forecasts range from $76.00 to $154.00. On average, they expect Neurocrine Biosciences' share price to reach $112.21 in the next twelve months. This suggests a possible upside of 30.7% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences or view top-rated stocks among Wall Street analysts.

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:

• Dr. Kevin C. Gorman Ph.D., CEO & Director (Age 64, Pay $1.58M)
• Mr. Matthew C. Abernethy, Chief Financial Officer (Age 42, Pay $906.76k) (LinkedIn Profile)
• Dr. Jude Onyia Ph.D., Chief Scientific Officer (Age 58, Pay $621.66k)
• Mr. Eric S. Benevich, Chief Commercial Officer (Age 57, Pay $805k) (LinkedIn Profile)
• Dr. Eiry Wyn Roberts, Chief Medical Officer (Age 58, Pay $925.46k)
• Dr. Dimitri E. Grigoriadis, Chief Research Officer (Age 64) (LinkedIn Profile)
• Jane Sorensen, Head of Investor Relations
• Mr. Darin M. Lippoldt, Chief Legal Officer & Corp. Sec. (Age 56) (LinkedIn Profile)
• Mr. Kyle W. Gano, Chief Bus. Devel. and Strategy Officer (Age 49) (LinkedIn Profile)
• Ms. Julie S. Cooke, Chief HR Officer (Age 56) (LinkedIn Profile)

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Neurocrine Biosciences' key competitors?

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), United Therapeutics (UTHR), Repligen (RGEN), Halozyme Therapeutics (HALO), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all of NBIX's competitors.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Square (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.18%), Bellevue Group AG (3.16%), Bank of New York Mellon Corp (1.78%), Deerfield Management Company L.P. Series C (1.73%), Eaton Vance Management (1.52%) and DSM Capital Partners LLC (1.41%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends for Neurocrine Biosciences.

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Eaton Vance Management, Zurcher Kantonalbank Zurich Cantonalbank , BNP Paribas Arbitrage SA, Citigroup Inc., Bank of New York Mellon Corp, Bellevue Group AG, Renaissance Technologies LLC, and Verition Fund Management LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin, and William H Rastetter.
View insider buying and selling activity for Neurocrine Biosciences or view top insider-selling stocks.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was bought by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, American Century Companies Inc., Wellington Management Group LLP, Deerfield Management Company L.P. Series C, GW&K Investment Management LLC, Congress Asset Management Co. MA, Connor Clark & Lunn Investment Management Ltd., and Rice Hall James & Associates LLC.
View insider buying and selling activity for Neurocrine Biosciences or or view top insider-buying stocks.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $85.84.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences has a market capitalization of $8.20 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.72 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

Neurocrine Biosciences employs 900 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 617-7600, via email at [email protected], or via fax at 858-617-7602.